Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CLK4 | Q9HAZ1 | 8/20 | 0.57 |
| ▸ | DYRK1A | Q13627 | 5/20 | 0.57 |
| ▸ | CLK1 | P49759 | 3/20 | 0.57 |
| ▸ | DYRK1B | Q9Y463 | 3/20 | 0.57 |
| ▸ | CLK2 | P49760 | 2/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.48 |
| ▸ | RAF1 | P04049 | 1/20 | 0.48 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.48 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.48 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.48 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.48 |
| ▸ | PDE2A | O00408 | 1/20 | 0.48 |
| ▸ | CDK1 | P06493 | 3/20 | 0.46 |
| ▸ | CCNB2 | O95067 | 2/20 | 0.46 |
| ▸ | CCNB1 | P14635 | 2/20 | 0.46 |
| ▸ | CCNB3 | Q8WWL7 | 2/20 | 0.46 |
| ▸ | VNN1 | O95497 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13384583 | 0.84 | KDM4E (0.45) | CLK4CLK1 | |
| SCHEMBL29734823 | 0.82 | CLK4 (0.60) | CLK4DYRK1ACLK1DYRK1BCLK2 | |
| SCHEMBL10224746 | 0.81 | CLK4 (0.61) | CLK4DYRK1ACLK1DYRK1BCLK2 | |
| SCHEMBL19407789 | 0.81 | CLK4 (0.72) | CLK4DYRK1ACLK1DYRK1BCLK2 | |
| SCHEMBL12362922 | 0.79 | CLK4 (0.67) | CLK4DYRK1ACLK1DYRK1BCLK2 | |
| SCHEMBL84031 | 0.79 | CDK1 (0.47) | CDK1VNN1 | |
| SCHEMBL5622343 | 0.78 | VNN1 (0.59) | CLK4DYRK1ACLK1DYRK1BCLK2 | |
| SCHEMBL12362921 | 0.76 | CLK4 (0.53) | CLK4DYRK1ACLK1DYRK1BCLK2 | |
| SCHEMBL84026 | 0.75 | ACACB (0.40) | — | |
| SCHEMBL84455 | 0.75 | MKNK1 (0.48) | CLK4CLK2MAPK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8865732-B2 | Heterocyclic compounds and uses thereof | NOVARTIS AG (CH) | 2014-10-21 | — | — | US | disclosed |
| US-20130210818-A1 | Novel Heterocyclic Compounds and Uses Thereof | NOVARTIS AG (CH) | 2013-08-15 | — | — | US | disclosed |
| US-8129394-B2 | Heteroaryl-substituted imidazole compounds and uses thereof | NOVARTIS AG (CH) | 2012-03-06 | — | — | US | disclosed |
| US-8129394-B2 | Heteroaryl-substituted imidazole compounds and uses thereof | NOVARTIS AG (CH) | 2012-03-06 | — | — | US | disclosed |
| US-20100003246-A1 | Novel heterocyclic compounds and uses therof | NOVARTIS AG (CH) | 2010-01-07 | — | — | US | disclosed |
| US-20100003246-A1 | Novel heterocyclic compounds and uses therof | NOVARTIS AG (CH) | 2010-01-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100003246-A1 | Novel heterocyclic compounds and uses therof | BRAF, ARAF, KRAS | CLK4 974/4885DYRK1A 776/4885CLK1 681/4885 |
| US-20130210818-A1 | Novel Heterocyclic Compounds and Uses Thereof | BRAF, RAF1, HRAS | CLK4 1046/4885DYRK1A 1628/4885CLK1 596/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.